跳至主要内容
临床试验/IRCT201105301155N14
IRCT201105301155N14已完成2 期

Efficacy of suppository naproxen in preventation of post ERCP pancreatitis in patients referred to RAZI hospital in RASHT

Behvazan Company0 个研究点目标入组 324 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
324

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • All patients over 18 years who were referred to hospital for ERCP; disorders in liver function tests; had extrahepatic cholestasis.
  • Exclusion criteria: Acute pancreatitis in the last two weeks; history of chronic pancreatitis; a history of previous sphincterotomy; NSAID use in a week; contraindication for NSAID use such as renal failure and having allergy to the drug; peptic ulcer with recent GI bleeding; not consent to participate in this plan.

排除标准

  • 未提供

研究者

发起方
Behvazan Company

相似试验